Loading clinical trials...
Loading clinical trials...
Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Queen Mary University of London
NCT07663266 · Multiple Sclerosis, Spinal Cord Injury
NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue
NCT06782490 · Multiple Sclerosis Spasticity
NCT07299019 · Secondary Progressive Multiple Sclerosis
Queen Mary University of London
London, England
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions